Title of the article: Current Review of the SARS-CoV-2 Omicron Subvariant BF.7 (BA.5.2.1.7) Virology and Preventing Strategies.

Abstract

Since its identification in late 2019 the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) In Wuhan, China, by the World Health Organization (WHO), which cause the coronavirus disease 2019, it is rapidly spreading, resulting in the global pandemic. As of 19 December 2022, a total of 64 million (649,038,437) confirmed cases including 6,645,812 deaths have been reported across the world. Over time, the SARS-CoV-2 acquired genetic mutations resulting in multiple types of SARS-CoV-2 variants and subvariants that have been confirmed. The Omicron (B.1.1.529) variant was identified later in November 2021, with enhanced immune escape and was followed with various sublineages BA.1, BA.2, BA.3, BA.4 and BA.5 and Other sublineages BQ.1, BQ.11, BF.7, BA.2.75, and XBB due to mutations in the spike protein of the SARS-CoV-2. In response to the current surge in the COVID-19 reports by Omicron subvariant BF.7 also known as BA.2.75.2, in China and other countries, triggering global alarm. The present review was conducted to understand the virology, factors associated with increased transmissibility with BF.7 and possible urgent preventing strategies to be taken to curtail the novel omicron variants outbreak across the world.